Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
Source: View publication →
In patients with previously untreated, advanced ALK-positive non–small cell lung cancer, first-line lorlatinib demonstrated unprecedented long-term efficacy with a 5-year progression-free survival rate of 60% compared to 8% with crizotinib.
Key Findings
Study Design
Study Limitations
Clinical Significance
The CROWN trial results establish lorlatinib as the preferred first-line standard of care for advanced ALK-positive NSCLC. The unprecedented 5-year PFS and robust CNS activity provide a new benchmark for targeted therapy efficacy, significantly altering the treatment paradigm by providing durable disease control that potentially avoids the need for early sequential TKI therapy.
Historical Context
Crizotinib was the first-generation ALK-TKI that initially established the efficacy of targeting ALK rearrangements in NSCLC. Subsequent generations, including alectinib and brigatinib, improved upon crizotinib's efficacy and brain penetration. The CROWN trial represents the culmination of this evolution, demonstrating that the third-generation inhibitor, lorlatinib, provides superior, long-term systemic and intracranial control, setting a new high-water mark for molecularly targeted therapy.
Guided Discussion
High-yield insights from every perspective
What is the primary mechanism of action of lorlatinib, and why is its ability to penetrate the blood-brain barrier (BBB) clinically significant for patients with ALK-positive non-small cell lung cancer (NSCLC)?
Key Response
Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI). Unlike first-generation crizotinib, it was macrocyclized to enhance potency and BBB penetration. This is crucial because the central nervous system (CNS) is a common site of relapse and metastasis in ALK-positive NSCLC; effectively treating or preventing brain metastases is a key component of improving long-term survival.
In the context of the 5-year CROWN study results, how should a clinician manage the specific metabolic and neurocognitive side effects unique to lorlatinib compared to earlier-generation ALK inhibitors?
Key Response
Lorlatinib is associated with unique toxicities including hyperlipidemia, weight gain, and cognitive effects (e.g., memory impairment or mood changes). Residents must recognize that while lorlatinib has superior efficacy, management requires frequent lipid monitoring (often requiring statins) and proactive screening for neuropsychiatric symptoms, which may necessitate dose interruptions or reductions without necessarily compromising the unprecedented progression-free survival (PFS) benefit.
The CROWN trial reports a 5-year PFS rate of 60% for lorlatinib versus 8% for crizotinib. How does this result impact the sequence of therapy for a patient who might otherwise have started on a second-generation TKI like alectinib or brigatinib?
Key Response
While alectinib and brigatinib are established first-line options, the CROWN data shows a hazard ratio of 0.19, the lowest ever reported in advanced NSCLC. Fellows must weigh this superior 'front-loading' of the most potent agent against the risk of exhausting treatment options, especially since lorlatinib can overcome many resistance mutations (like G1202R) that develop after second-generation TKIs. The debate centers on whether starting with the 'best' drug (lorlatinib) outweighs the traditional sequential approach.
With the 5-year PFS curve for lorlatinib appearing to plateau at 60%, can we now realistically discuss 'functional cure' or exceptional long-term survivorship in the first-line metastatic ALK+ setting?
Key Response
An attending-level perspective recognizes that a 60% PFS at five years is transformative. This suggests a subset of patients may achieve durable, long-term remission previously unseen in metastatic lung cancer. This shift requires re-evaluating patient counseling from a 'palliative' mindset to one of 'chronic disease management' or 'long-term survivorship,' focusing on quality of life and long-term toxicity monitoring.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
From a methodological standpoint, how does the choice of crizotinib as the control arm in the CROWN trial—given that it was already being superseded by second-generation TKIs during the study period—limit our ability to perform a network meta-analysis comparing lorlatinib to alectinib?
Key Response
The use of an active but 'sub-optimal' control (crizotinib) creates a 'trial-lag' effect. While the efficacy against crizotinib is clear, the lack of a head-to-head comparison with alectinib or brigatinib means researchers must rely on cross-trial comparisons and indirect treatment comparisons (ITCs). PhDs would critique the hazard ratios generated via ITCs, noting that differences in patient populations and CNS imaging protocols across trials can confound the perceived superiority of one third-generation agent over second-generation ones.
Despite the remarkable PFS benefit, the overall survival (OS) data in the CROWN 5-year update remains immature. What are the editorial concerns regarding the potential for subsequent treatments to confound OS, and is PFS a sufficient primary endpoint for regulatory and clinical consensus in this specific genetic niche?
Key Response
Editors must evaluate if PFS is a valid surrogate for OS in ALK+ disease, where patients often live for many years across multiple lines of therapy. With a 60% PFS at five years, waiting for mature OS data could take a decade. The editorial challenge is to determine if the magnitude of PFS improvement (HR 0.19) is so clinically significant that it justifies practice change even in the absence of a definitive OS advantage, which may be perpetually masked by crossover and subsequent TKI use.
Based on the 5-year CROWN outcomes, should lorlatinib be elevated to the sole 'Preferred' Category 1 recommendation for ALK+ NSCLC, and how should guidelines address its use in patients with baseline brain metastases vs. those without?
Key Response
Current NCCN and ESMO guidelines include lorlatinib, alectinib, and brigatinib as first-line options. The committee must decide if the 60% 5-year PFS justifies prioritizing lorlatinib over alectinib (which has a 5-year PFS of approx. 35% in the ALEX trial). The rationale must balance the superior intracranial efficacy and PFS of lorlatinib against the more favorable safety profile of second-generation agents, potentially leading to a nuanced recommendation based on CNS disease burden and patient comorbidities.
Clinical Landscape
Noteworthy Related Trials
PROFILE 1014 Trial
Tested
Crizotinib
Population
Treatment-naive patients with advanced ALK-positive NSCLC
Comparator
Platinum-doublet chemotherapy
Endpoint
Progression-free survival
ALEX Trial
Tested
Alectinib
Population
Treatment-naive patients with advanced ALK-positive NSCLC
Comparator
Crizotinib
Endpoint
Progression-free survival
ALTA-1L Trial
Tested
Brigatinib
Population
Treatment-naive patients with advanced ALK-positive NSCLC
Comparator
Crizotinib
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis